Cambrex has completed the first phase of its $30 million investment in its small molecule active pharmaceutical ingredient (API) manufacturing facility in High Point, NC. The newly constructed space adds analytical and chemical development labs totaling 30,000 square feet and provides future workspace for 85 analytical and chemical development scientists. These labs will support the development of APIs to be manufactured in the facility’s current clinical manufacturing area, as well as the future expanded clinical manufacturing and commercial manufacturing suites.
 
“With the growing number of therapies in clinical development and trend toward more targeted therapeutics, including orphan drugs, this expansion is preparing Cambrex to support the growing demand for small-scale API manufacturing,” said Tom Loewald, CEO, Cambrex. “Our expansion goes beyond providing capacity – it provides state-of-the-art technology and laboratory equipment, an energy efficient infrastructure, and an ideal space for our scientific experts to work side-by-side with our clients.”
 
Phase 2 of the project is ongoing and will approximately double the facility’s manufacturing capacity with the addition of clinical and commercial manufacturing suites with reactors up to 2,000 liters. The new commercial area will provide an ideal scale for the manufacturing of orphan drugs and niche therapies, while larger volume products developed at the facility can be manufactured commercially at one of Cambrex’s larger scale facilities in Iowa and Sweden. This expansion follows Cambrex’s 2021 investment in the Cambrex High Point continuous flow R&D center of excellence, including expanded capabilities for continuous flow process development, manufacturing, and scale up.